Name | Title | Contact Details |
---|
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.
Helm Pharmaceuticals is a Chappaqua, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MapLight Therapeutics is developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders. Today, there are few therapeutic options for people living with conditions such as schizophrenia, Alzheimer`s disease, Parkinson`s, and autism spectrum disorder. Available treatments are limited by modest efficacy and significant side effects. MapLight is committed to redefining this standard of care. The company`s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and treat those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of the two groundbreaking technologies, optogenetics and STARmap.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Progenika is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.